An FDA panel voted 15-1 to endorse Boehringer Ingelheim's olodaterol as a treatment for chronic obstructive pulmonary disease. The panel believed that Boehringer provided substantial evidence of the safety and long-term efficacy of the drug, which would be sold as a soft mist inhaler under the name Striverdi Respimat.

Related Summaries